Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPlas Study
2024-518668-11-01Phase 2Authorised
- Sponsor
- Norwegian University of Science and Technology
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of octaplas lg and ExPlas in Alzheimer's disease (AD) (3 arms), sponsored by Norwegian University of Science and Technology. Primary endpoints: Safety and tolerability and Feasibility. Planned start Jan 2025; status: authorised.
02
Drugs
octaplas lgExPlas
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-518668-11-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518668-11-01.